Support

A cookie is a piece of data stored by your browser or device that helps websites like this one recognize return visitors. We use cookies to give you the best experience on BNA.com. Some cookies are also necessary for the technical operation of our website. If you continue browsing, you agree to this site’s use of cookies.

Marketing Services

Bloomberg Next marketing services allow clients to elevate their brands and extend their reach through our established and trusted expertise, enhanced with engaging event production, appealing design, and compelling messaging.

FDA Mulling Ways to Break Silos, Review Products by Clinical Areas

Nov. 4 — The FDA is considering ways to review more medical treatments by clinical area, following
in the steps of the cancer center established this summer.

“Historically, as almost everyone knows, FDA has been remarkably siloed,” Food and
Drug Administration Commissioner Robert M. Califf said Nov. 4. “But what you hear
loud and clear from patients is they’d like a have a way to be in contact with the
FDA that’s not by product type but by what’s relevant to their disease. And we obviously
heard that loud and clear from the cancer patients.”

Califf delivered the keynote address at a biopharmaceutical conference organized in
part by the
Friends of Cancer Research—the group that successfully lobbied for the
FDA Center for Excellence the agency established in June. An effort to streamline approval of cancer products
by bringing together reviewers from all the different FDA device, drug and biologic
centers, the center is part of the agency’s effort to support the
White House cancer moonshot initiative.

This new approach to review also has implications to advance precision medicine—another
Obama administration priority—since a critical component of these targeted treatments is the use of a diagnostic
tool to determine if a patient will benefit from a treatment.

From Silos to Matrix

For a whole host of reasons, Califf said, the FDA didn’t follow academia and industry
as they restructured from a siloed approach to a more integrated, or “matrix” approach
15 to 20 years ago. The Oncology Center for Excellence was the first step in responding
to the call to look at medical products by clinical relevance and not by their classification
as a drug, device or biologic.

“Exactly how far the matrix goes is a matter of discussion,” Califf said. “And it
may be quite different for different fields.”

While there may be reason to have cohesion around the clinical portion of experimental
treatments, different products have fundamental qualities that still may warrant review
from the different centers.

“Devices are very iterative. They’re engineering. They’re fundamentally very different
from drugs,”
Califf said. “And I’ve learned that bioloigcs are somewhere in the middle. There’s
a lot of tweaking that can and does go on with biologics.”

Two Priorities

In the final days of the Obama administration, Califf identified two of his overarching
priorities, in addition to specific policy topics such as opioid addiction. The first
is revamping the human resources system to enable the FDA to hire the staff it needs
to keep pace with what he described as “an amazing explosion of biotechnology.”

The second priority is what he described as an “evidence generation” by harnessing
available data to help inform the agency’s regulatory decisions. Califf cited the
FDA’s
Sentinel Initiative, which pulls information from electronic health records (EHR), insurance claims data
and registries and other data sources to develop postmarket risk identification and
analysis systems.

Califf added that most of the decisions about what’s not working are made “well before
anyone would think about putting an application together.”

“Given that 92 percent of drugs that get to phase I don’t make it to market, this
is really critical,”
he said.

Phase I refers to the first time an investigational product gets tested on humans,
usually for safety and dosage purposes, not to determine if the drug actually works.

New Drug Approvals Drop by Half

In a separate session, John Jenkins, director of the FDA Office of New Drugs, said
the agency has approved 19 novel drugs. This number is less than half the new drugs the agency has approved in previous years.
In
2015, the FDA approved 45 new drugs and in
2014
it approved 41.

Jenkins said the drop-off is due to fewer applications coming in to the FDA combined
with fewer approvals after the first review cycle.

Rejections often arise from problems meeting manufacturing standards instead of a
lack of substantial evidence that the investigational drug didn’t work. “It’s not
a lack of effort on our part. It’s more deficiencies that just didn’t meet the standards,”
Jenkins said.

To contact the reporter on this story: Jeannie Baumann in Washington at
jbaumann@bna.com

To contact the editor responsible for this story:
Randy Kubetin at
RKubetin@bna.com

All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to books@bna.com.

Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)

Notify me when updates are available (No standing order will be created).

This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to research@bna.com.

Put me on standing order

Notify me when new releases are available (no standing order will be created)